Annual Cash & Cash Equivalents
$10.37 B
-$134.90 M-1.28%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual cash & cash equivalents is currently $10.37 billion, with the most recent change of -$134.90 million (-1.28%) on 31 December 2023. During the last 3 years, it has risen by +$4.38 billion (+73.16%). VRTX annual cash & cash equivalents is now -1.28% below its all-time high of $10.50 billion, reached on 31 December 2022.VRTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$5.24 B
+$659.10 M+14.39%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly cash and cash equivalents is currently $5.24 billion, with the most recent change of +$659.10 million (+14.39%) on 30 September 2024. Over the past year, it has dropped by -$5.87 billion (-52.84%). VRTX quarterly cash and cash equivalents is now -52.84% below its all-time high of $11.11 billion, reached on 30 September 2023.VRTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.3% | -52.8% |
| 3 y3 years | +73.2% | -16.5% |
| 5 y5 years | +291.3% | +54.2% |
VRTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -1.3% | +73.2% | -52.8% | +14.4% |
| 5 y | 5 years | -1.3% | +291.3% | -52.8% | +68.5% |
| alltime | all time | -1.3% | >+9999.0% | -52.8% | >+9999.0% |
Vertex Pharmaceuticals Incorporated Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $5.24 B(+14.4%) |
| June 2024 | - | $4.58 B(-50.0%) |
| Mar 2024 | - | $9.16 B(-11.7%) |
| Dec 2023 | $10.37 B(-1.3%) | $10.37 B(-6.7%) |
| Sept 2023 | - | $11.11 B(+9.4%) |
| June 2023 | - | $10.15 B(+9.3%) |
| Mar 2023 | - | $9.29 B(-11.6%) |
| Dec 2022 | $10.50 B(+54.6%) | $10.50 B(+14.5%) |
| Sept 2022 | - | $9.17 B(+5.4%) |
| June 2022 | - | $8.70 B(+14.5%) |
| Mar 2022 | - | $7.60 B(+11.8%) |
| Dec 2021 | $6.79 B(+13.5%) | $6.79 B(+8.3%) |
| Sept 2021 | - | $6.28 B(+3.5%) |
| June 2021 | - | $6.06 B(-3.8%) |
| Mar 2021 | - | $6.30 B(+5.3%) |
| Dec 2020 | $5.99 B(+92.6%) | $5.99 B(+11.8%) |
| Sept 2020 | - | $5.36 B(+10.9%) |
| June 2020 | - | $4.83 B(+34.4%) |
| Mar 2020 | - | $3.59 B(+15.6%) |
| Dec 2019 | $3.11 B(+17.3%) | $3.11 B(-8.5%) |
| Sept 2019 | - | $3.40 B(+3.1%) |
| June 2019 | - | $3.29 B(+13.8%) |
| Mar 2019 | - | $2.89 B(+9.2%) |
| Dec 2018 | $2.65 B(+59.1%) | $2.65 B(+6.9%) |
| Sept 2018 | - | $2.48 B(+15.5%) |
| June 2018 | - | $2.15 B(+7.5%) |
| Mar 2018 | - | $2.00 B(+19.8%) |
| Dec 2017 | $1.67 B(+40.7%) | $1.67 B(+20.2%) |
| Sept 2017 | - | $1.38 B(+13.2%) |
| June 2017 | - | $1.22 B(+21.9%) |
| Mar 2017 | - | $1.00 B(-15.2%) |
| Dec 2016 | $1.18 B(+65.6%) | $1.18 B(+64.5%) |
| Sept 2016 | - | $719.69 M(+18.8%) |
| June 2016 | - | $605.87 M(+0.3%) |
| Mar 2016 | - | $604.25 M(-15.5%) |
| Dec 2015 | $714.77 M(+14.3%) | $714.77 M(-5.5%) |
| Sept 2015 | - | $756.25 M(-13.1%) |
| June 2015 | - | $870.54 M(+30.9%) |
| Mar 2015 | - | $664.88 M(+6.3%) |
| Dec 2014 | $625.26 M(+9.8%) | $625.26 M(-13.0%) |
| Sept 2014 | - | $718.56 M(+70.9%) |
| June 2014 | - | $420.56 M(-0.8%) |
| Mar 2014 | - | $424.05 M(-25.5%) |
| Dec 2013 | $569.30 M(+16.3%) | $569.30 M(-2.4%) |
| Sept 2013 | - | $583.18 M(+9.8%) |
| June 2013 | - | $531.25 M(+40.1%) |
| Mar 2013 | - | $379.10 M(-22.5%) |
| Dec 2012 | $489.41 M(+3.0%) | $489.41 M(+12.0%) |
| Sept 2012 | - | $436.89 M(-3.8%) |
| June 2012 | - | $454.06 M(+69.5%) |
| Mar 2012 | - | $267.92 M(-43.6%) |
| Dec 2011 | $475.32 M(+95.4%) | $475.32 M(-12.4%) |
| Sept 2011 | - | $542.54 M(+18.4%) |
| June 2011 | - | $458.19 M(+2.6%) |
| Mar 2011 | - | $446.54 M(+83.6%) |
| Dec 2010 | $243.20 M(-45.6%) | $243.20 M(-57.3%) |
| Sept 2010 | - | $569.90 M(+68.8%) |
| June 2010 | - | $337.61 M(-14.9%) |
| Mar 2010 | - | $396.55 M(-11.2%) |
| Dec 2009 | $446.66 M(+14.8%) | $446.66 M(-20.1%) |
| Sept 2009 | - | $559.13 M(+36.7%) |
| June 2009 | - | $408.95 M(-32.1%) |
| Mar 2009 | - | $602.20 M(+54.8%) |
| Dec 2008 | $389.12 M(+9.4%) | $389.12 M(-28.3%) |
| Sept 2008 | - | $542.88 M(-1.2%) |
| June 2008 | - | $549.63 M(+12.0%) |
| Mar 2008 | - | $490.70 M(+38.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $355.66 M(+66.8%) | $355.66 M(+40.0%) |
| Sept 2007 | - | $253.98 M(+50.5%) |
| June 2007 | - | $168.72 M(-52.4%) |
| Mar 2007 | - | $354.33 M(+66.2%) |
| Dec 2006 | $213.17 M(+173.1%) | $213.17 M(-55.9%) |
| Sept 2006 | - | $483.43 M(+1066.9%) |
| June 2006 | - | $41.43 M(-49.4%) |
| Mar 2006 | - | $81.83 M(+4.8%) |
| Dec 2005 | $78.05 M(+41.9%) | $78.05 M(-23.2%) |
| Sept 2005 | - | $101.62 M(-47.8%) |
| June 2005 | - | $194.69 M(+421.0%) |
| Mar 2005 | - | $37.37 M(-32.1%) |
| Dec 2004 | $55.01 M(-44.0%) | $55.01 M(+48.5%) |
| Sept 2004 | - | $37.04 M(-41.8%) |
| June 2004 | - | $63.69 M(+20.2%) |
| Mar 2004 | - | $53.01 M(-46.0%) |
| Dec 2003 | $98.16 M(-9.2%) | $98.16 M(+26.7%) |
| Sept 2003 | - | $77.45 M(-41.9%) |
| June 2003 | - | $133.41 M(-26.2%) |
| Mar 2003 | - | $180.77 M(+67.2%) |
| Dec 2002 | $108.10 M(-42.9%) | $108.10 M(+4.3%) |
| Sept 2002 | - | $103.59 M(-17.3%) |
| June 2002 | - | $125.27 M(-28.9%) |
| Mar 2002 | - | $176.23 M(-6.9%) |
| Dec 2001 | $189.21 M(-45.4%) | $189.21 M(-3.4%) |
| Sept 2001 | - | $195.95 M(+16.3%) |
| June 2001 | - | $168.53 M(-24.3%) |
| Mar 2001 | - | $222.66 M(-35.8%) |
| Dec 2000 | $346.66 M(+998.8%) | $346.66 M(-26.5%) |
| Sept 2000 | - | $471.43 M(+157.3%) |
| June 2000 | - | $183.21 M(-4.5%) |
| Mar 2000 | - | $191.75 M(+507.8%) |
| Dec 1999 | $31.55 M(+30.4%) | $31.55 M(+40.8%) |
| Sept 1999 | - | $22.40 M(+100.0%) |
| June 1999 | - | $11.20 M(-43.4%) |
| Mar 1999 | - | $19.80 M(-18.2%) |
| Dec 1998 | $24.20 M(-66.2%) | $24.20 M(-51.3%) |
| Sept 1998 | - | $49.70 M(+36.9%) |
| June 1998 | - | $36.30 M(-37.8%) |
| Mar 1998 | - | $58.40 M(-18.3%) |
| Dec 1997 | $71.50 M(+104.9%) | $71.50 M(-59.7%) |
| Sept 1997 | - | $177.20 M(-6.0%) |
| June 1997 | - | $188.60 M(+122.1%) |
| Mar 1997 | - | $84.90 M(+143.3%) |
| Dec 1996 | $34.90 M(+22.9%) | $34.90 M(-10.7%) |
| Sept 1996 | - | $39.10 M(+320.4%) |
| June 1996 | - | $9.30 M(-54.0%) |
| Mar 1996 | - | $20.20 M(-28.9%) |
| Dec 1995 | $28.40 M(-60.3%) | $28.40 M(-27.9%) |
| Sept 1995 | - | $39.40 M(-10.7%) |
| June 1995 | - | $44.10 M(-14.2%) |
| Mar 1995 | - | $51.40 M(-28.2%) |
| Dec 1994 | $71.60 M(+150.3%) | $71.60 M(+47.6%) |
| Sept 1994 | - | $48.50 M(+127.7%) |
| June 1994 | - | $21.30 M(-60.8%) |
| Mar 1994 | - | $54.30 M(+89.9%) |
| Dec 1993 | $28.60 M(+146.6%) | $28.60 M(+90.7%) |
| Sept 1993 | - | $15.00 M(+130.8%) |
| June 1993 | - | $6.50 M(-56.7%) |
| Mar 1993 | - | $15.00 M(+29.3%) |
| Dec 1992 | $11.60 M(-58.0%) | $11.60 M(-48.9%) |
| Sept 1992 | - | $22.70 M(+39.3%) |
| June 1992 | - | $16.30 M(-34.3%) |
| Mar 1992 | - | $24.80 M(-10.1%) |
| Dec 1991 | $27.60 M(+527.3%) | $27.60 M(+273.0%) |
| Sept 1991 | - | $7.40 M(+221.7%) |
| June 1991 | - | $2.30 M(-47.7%) |
| Dec 1990 | $4.40 M | $4.40 M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly cash and cash equivalents year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents?
The current annual cash & cash equivalents of VRTX is $10.37 B
What is the all time high annual cash & cash equivalents for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual cash & cash equivalents is $10.50 B
What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
Over the past year, VRTX annual cash & cash equivalents has changed by -$134.90 M (-1.28%)
What is Vertex Pharmaceuticals Incorporated quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VRTX is $5.24 B
What is the all time high quarterly cash and cash equivalents for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly cash and cash equivalents is $11.11 B
What is Vertex Pharmaceuticals Incorporated quarterly cash and cash equivalents year-on-year change?
Over the past year, VRTX quarterly cash and cash equivalents has changed by -$5.87 B (-52.84%)